Proteinase-3 as the major autoantigen of c-ANCA is strongly expressed in lung tissue of patients with Wegener's granulomatosis
© BioMed Central Ltd 2002
Received: 23 April 2001
Accepted: 4 January 2002
Published: 27 March 2002
Proteinase-3 (PR-3) is a neutral serine proteinase present in azurophil granules of human polymorphonuclear leukocytes and serves as the major target antigen of antineutrophil cytoplasmic antibodies with a cytoplasmic staining pattern (c-ANCA) in Wegener's granulomatosis (WG). The WG disease appears as severe vasculitis in different organs (e.g. kidney, nose and lung). Little is known about the expression and distribution of PR-3 in the lung. We found that PR-3 is expressed in normal lung tissue and is upregulated in lung tissue of patients with WG. Interestingly, the parenchymal cells (pneumocytes type I and II) and macrophages, and not the neutrophils, express PR-3 most strongly and may contribute to lung damage in patients with WG via direct interaction with antineutrophil cytoplasmic antobodies (ANCA). These findings suggest that the PR-3 expression in parenchymal cells of lung tissue could be at least one missing link in the etiopathogenesis of pulmonary pathology in ANCA-associated disease.
Keywordsgranuloma in situ hybridization pneumocytes proteinase-3 Wegener's granulomatosis
Proteinase-3 (PR-3) is a 29,000 Da neutral serine proteinase stored in the azurophil granules of polymorphonuclear leukocytes . An increasing number of physiological and pathological properties of PR-3 have been reported. PR-3 has broad proteolytic activity and degrades a variety of extracellular matrix proteins, including fibronectin, type IV collagen and laminin [2, 3]. PR-3 is identical to myeloblastin, which is a growth-promoting protein from myeloid cells . Via a nonproteolytic mechanism, PR-3 has potent antimicrobial activity both against bacteria and fungi [5, 6]. PR-3 was recently shown to induce apoptosis in cultured human endothelial cells . PR-3 is also identical to the target antigen (antineutrophil cytoplasmic antibodies with a cytoplasmic staining pattern [c-ANCA]) associated with some systemic vasculitides such as WG and microscopic polyarteritis . It is not yet known whether antineutrophil cytoplasmic antibodies (ANCA) are directly involved in the pathogenesis of WG or are merely an epiphenomenon [9–11].
It has previously been thought that PR-3 expression was confined to the promyelocytic/myelocytic stage of hematopoiesis . However, other cells are also capable of de novo synthesis of PR-3 mRNA. In vitro studies revealed that PR-3 expression can be induced by cytokines in human endothelial cells [13, 14].
The lung is the organ most frequently involved in WG, and in some cases it is the only organ affected . Given the potential importance of PR-3 in the pathogenesis of WG, we sought to define the expression pattern of PR-3 in lung tissue.
Materials and methods
Normal tissues were obtained from five patients undergoing total pneumonectomy because of lung cancer. Tissue samples were snap-frozen in OCT Tissue Tek embedding medium (Leica Instruments, Hamburg, Germany).
We also obtained samples from five patients with WG and a proven lung involvement from the Institute of Pathology, University of Bochum/Clinic Bergmannsheil. All of these patients had a c-ANCA titer of more than 1:160 (indirect immunofluorescence on alcohol-fixed neutrophils).
Northern blot analysis
Total RNA was isolated from normal lung tissue with RNeasy (Quiagen, Hilden, Germany) and used for preparation of mRNA with the mRNA isolation kit (Hoffmann-La Roche, Grenzach-Whylen, Germany). The northern blot was performed as described by Müller-Ladner et al. .
Preparation of the single-strand PR-3 RNA probe
The cDNA sequences, used as probes for the mRNA of PR-3 components, were obtained by RT-PCR of total cellular mRNA of HL-60 cells, a myelomonocytic cell line . The following primers were used in this study: PR-3 'sense', 5'-ATC-GTGGGCGGGCACGAGGCG (at the beginning of exon 2, corresponding to bases +82 to +101 of the cDNA); and PR-3 'antisense', 5'-GCGGCCAGGGAACGAAAGTGCA (at the end of exon 4, corresponding to bases +553 to +582). The expected size of the fragment was 500 base pairs. The cDNA fragment was extracted and purified from a preparative gel using the Wizard PCR preps DNA purification system (Promega A 7170, CA, USA) and subcloned into the polylinker site of bluescript SK+ (Stratagene, CA, USA).
Antisense and sense RNA probes were transcribed by T3 and T7 RNA polymerase using a commercially available RNA transcription kit, according to the protocol recommended by the manufacturer (Stratagene). Probes were labeled with Digoxigenin-UTP (Hoffmann-La Roche).
In situ hybridization
Frozen sections (4–6 μm) were cut, air-dried and fixed immediately in acetone for 15 min. Formaldehyde-fixed sections were deparaffinized according to standard procedure. The sections were prepared according to the method of Müller-Ladner et al. .
The slides were washed in Tris-NaCl (pH7.6) and incubated in Tris-NaCl containing 2% normal goat serum (to block nonspecific binding) for 30 min at room temperature, followed by incubation with antidigoxigenin-alkaline phosphatase-antibody complex (Hoffmann-La Roche) in Tris-NaCl (pH7.6) for 1 hour at room temperature. Then 45 μl NBT (Boehringer Mannheim, Germany), 35 μl BCIP (Hoffmann-La Roche) and 24 μl Levamisole (Hoffmann-La Roche) were solved in 10 ml polyvinyl alcohol in a darkened chamber. Two hundred milliliters were applied to each section and incubated for between 12 and 24 hours. The sections were then mounted with aqueous gel (Faramount; Dako, Glostrup, Denmark) or stored at 4°C in Tris (pH7.6) for double-labeling by the alkaline phosphatase–antialkaline phosphatase (APAAP) method (see later).
Immunohistochemical double-labeling (APAAP method)
Double-labeling was performed using the APAAP method, with monoclonal antibody against CD68 (macrophages mouse IgG, 1:50; Dako), CD15 (granulocytes IgM, 1:50; Dianova, Hamburg, Germany), CD20 (B lymphocytes, 1:50; Dako), CD3 (T lymphocytes, 1:50; Dako), and Cytokeratin 8 and 19 (mouse IgG1, 1:25 and 1:200; Hoffmann-La Roche). Paraffin sections were prepared as described by Müller-Ladner et al. .
Double-labeling with biotin/fluorescence-coupled lectins
PR-3 hybridized sections were overlaid with fluorescein isothiocyanate/biotin-coupled Bauhinia purpurea and Maclura pomifera lectin diluted 1:200 and 1:500, respectively, for 30 min. Subsequently, slides were sequentially analyzed with light and fluorescent microscopy. The lectin of B. purpurea binds specifically to pneumocytes type I, whereas the lectin of M. pomifera binds to pneumocytes type II.
Microscopic evaluation and semiquantitative analysis of PR-3 mRNA expression
Sections were examined and photographed with a Leica Microscope DMRX (Leitz, Wetzlar, Germany). For quantitative analysis, a representative area between 1000 and 10,000 cells depending on the specimen was defined. In the representative areas, positive cells for PR-3 mRNA were scored in a semiquantitative fashion as follows: -, no positive cells; (+), <5% of cells positive; +, between 5% and 30% of cells positive; ++, between 30 and 60% of cells positive; +++, >60% of cells positive.
Northern blot analysis
In situ hybridization for PR-3 mRNA in normal lung
Characterization of PR-3 mRNA-positive cells in normal lung
In situ hybridization for PR-3 mRNA in lung tissue of WG patients
Semiquantitative analysis of proteinase-3 mRNA expression in normal lung and Wegener's granulomatosis (WG) lung specimens.
Characterization of PR-3 mRNA-positive cells in WG tissue
We found PR-3 mRNA expression mostly in pneumocytes type I and II. In comparison with normal tissue, however, there was a higher number of infiltrating, PR-3 expressing cells, different from pneumocytes.
Expression of the PR-3 protein in normal lung and WG tissue
To visualize the PR-3 protein expression, we performed immunohistological experiments with a monoclonal antibody (WGM2) from mice, specific for PR-3.
The diagnosis and classification of WG and related vasculitides were advanced considerably by characterization of serum antibodies that react with PR-3 (c-ANCA) . It is not yet known whether ANCA are directly involved in the pathogenesis of WG or are merely an epiphenomenon . One of the unresolved issues is the inability to explain the nonrandom, selected organ injury that defines the WG vasculitis and the concurrent, seemingly random, nature of injury within 'targeted' organs . Little is known about the expression and distribution of PR-3 in the normal lung and in the lung tissue of patients with WG.
To contribute to this little-known issue, we examined the PR-3 expression in normal lung and lung tissue of WG patients, as the lung is the most frequent organ involved in WG . In normal lung tissue, mainly pneumocytes type I and type II and just a few granulocytes and macrophages express PR-3. We could detect the PR-3 mRNA expression in pneumocytes especially at sites with an increased number of infiltrating macrophages. Speculatively, these cells could be responsible for initiating PR-3 mRNA expression; probably through changing the microenvironmental cytokine levels. Cytokines like interleukin-1 and tumor necrosis factor-α, secreted from macrophages, can induce PR-3 mRNA in nonhematopoietic cells .
The different expression of PR-3 in pneumocytes could also be due to variations of transcription factors. One possible candidate gene could be PU.1, which regulates the PR-3 transcription in B cells and macrophages. The expression in other nonhematopoietic cells, in particular pneumocytes, has not been extensively investigated [20, 21]. Although expressed in a very small amount in normal lung tissue, a question concerning the function of PR-3 in normal lung arose, since the occurrence of a proteolytic enzyme like PR-3 should not be favorable in this tissue . It is tempting to speculate that PR-3 could also play a role in microbiologic defense, since the enzyme also has an antimicrobial function . Further studies are clearly needed to elucidate the function of PR-3 in pneumocytes.
After we had proven that PR-3 mRNA is expressed in normal lung tissue, we questioned whether the expression pattern is different in the lung tissue of WG patients. The examined specimens of patients with WG showed strong PR-3 mRNA expression, with a double to threefold PR-3 mRNA increase compared with normal lung tissue. Similar to our findings in normal lung tissue, we could demonstrate in lung tissue of WG patients that PR-3 is mostly expressed in pneumocytes type I and type II. PR-3 expression was pronounced at sites of inflammatory infiltration, vasculitis and granulomas. In comparison with normal lung tissue, however, there was a higher number of infiltrating PR-3 expressing cells, which were not pneumocytes.
Apart from some PR-3 expressing granulocytes, most of the infiltrating PR-3 expressing cells were macrophages. One explanation for the occurrence of PR-3-positive macrophages in inflammatory tissue is the invasion of circulating monocytes to inflammatory sites. Just et al. showed an upregulation of PR-3 mRNA expression especially in circulating monocytes, but not in neutrophils, in patients with cystic fibrosis . We found PR-3 mRNA expression in and around vascular structures and vasculitic lesions, where most of the infiltrating cells were characterized as macrophages. However, a few cells seemed to be endothelial cells. This is in line with our recent findings of de novo synthesis of PR-3 in endothelial cells . On the contrary, most endothelial cells (even at multiple sites of acute vasculitis with inflammatory cells, invading the vessel and the surrounding tissue), were negative for PR-3 mRNA. Recent studies on the kinetics and stability of PR-3 transcripts revealed PR-3 mRNA expression is only transiently upregulated in endothelial cells .
The histological features within the WG specimens varied considerably with different inflammatory infiltrates and with or without granulomas. The only apparent issue the WG specimens have in common is the upregulation of PR-3 throughout the whole specimen. The upregulation of PR-3 in the lung of WG patients may therefore reflect the selected organ injury, whereas the histological heterogeneity may represent a multiplicity of concurrent immune responses to a unique disease precipitant like PR-3.
As it is most probable that pneumocytes, vascular endothelial cells and renal epithelial cells are no longer only innocent bystanders but active participants in inflammatory reactions of autoimmune vasculitides such as WG, it is very important to study the expression pattern of PR-3 in other organs or tissues that are involved in the manifestation pattern of WG . Schwarting et al. showed the in vitro expression of PR-3 mRNA in tubular epithelial cells and glomerular epithelial cells of the kidney . In vivo experiments in the kidney revealed a PR-3 expression in distal tubular epithelial cells and in the glomerulum. The PR-3 mRNA expressed by human glomerular epithelial cells correlates with crescent formation in patients with WG .
We thus envision that the upregulation of PR-3 in parenchymal lung tissue in patients with WG, probably through an altered cytokine pattern, can lead to PR-3/ ANCA-mediated lung damage. Further in vitro experiments and functional studies with pneumocytes will show whether the interaction of anti-PR-3 antibodies with pneumocytes will also activate signal transduction events or the expression of chemokines or adhesion molecules.
In conclusion, we report for the first time that PR-3 mRNA, the target antigen for c-ANCA, is expressed by normal lung parenchymal cells and is upregulated in lung tissue of WG patients. PR-3 mRNA may therefore contribute to lung damage in WG and other ANCA-associated diseases via direct interaction.
antineutrophil cytoplasmic antibodies
alkaline phosphatase–antialkaline phosphatase
antineutrophil cytoplasmic antibodies with a cytoplasmic staining pattern
reverse transcriptase-polymerase chain reaction.
The authors wish to thank Ms Huong Becker for excellent technical assistance and Dr E Csernok, Bad Bramstedt, for providing the monoclonal anti-PR-3 antibody WGM2.
- Rao NV, Wehner NG, Marshall BC, Gray WR, Gray BH, Hoidal JR: Characterization of proteinase-3 (PR-3), a neutrophil serine proteinase. Structural and functional properties. J Biol Chem. 1991, 35: 9540-9548.Google Scholar
- Campanelli D, Melchior M, Fu Y, Nakata N, Shuman H, Nathan C, Gabay JE: Cloning of cDNA for proteinase 3: a serine protease, antibiotic and autoantigen from human neutrophils. J Exp Med. 1990, 172: 1709-1715.PubMedView ArticleGoogle Scholar
- Kao RC, Wehner NG, Skubitz KM, Gray BH, Hoidal JR: Proteinase 3. A distinct human polyporphonuclear leukocyte proteinase that produces emphysema in hamsters. J Clin Invest. 1988, 82: 1963-1973.PubMedPubMed CentralView ArticleGoogle Scholar
- Bories D, Raynal MC, Solomon DH, Darzynkiewicz Z, Cayre Y: Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell. 1989, 59: 959-968.PubMedView ArticleGoogle Scholar
- Campanelli D, Detmers PA, Nathan CF, Gabay JE: Azurocidin and a homologous serine protease from neutrophils. Differential antimicrobial and proteolytical properties. J Clin Invest. 1990, 85: 904-915.PubMedPubMed CentralView ArticleGoogle Scholar
- Gabay JE, Scott RW, Campanelli D: Antibiotic proteins of human polymorphonuclear leukocytes. Proc Natl Acad Sci USA. 1989, 86: 5610-5614.PubMedPubMed CentralView ArticleGoogle Scholar
- Yang JJ, Kettritz R, Falk RJ, Jennette JC, Gaido ML: Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase. Am J Pathol. 1996, 149: 1617-1626.PubMedPubMed CentralGoogle Scholar
- Laevitt Ry, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, Lie JT, Lightfoot RW, Masi AT, McShane DJ, Mills JA, Stevens MB, Wallace SL, Zvaifler NJ: The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990, 33: 1101-1107.View ArticleGoogle Scholar
- Van der Woude FJ, Van Es LA, Daha MR: The role of the cANCA antigen in the pathogenesis of Wegener's granulomatosis. A hypothesis based on both humoral and cellular mechanisms. Neth J Med. 1990, 36: 169-171.PubMedGoogle Scholar
- Kallenberg CGM, Brouwer E, Mulder AHL, Stegeman CA, Weening JJ, Cohen Tervaert JW: ANCA – pathophysiology revisited [review]. Clin Exp Immunol. 1995, 100: 1-3.PubMedPubMed CentralView ArticleGoogle Scholar
- Falk RJ, Hogan S, Carey TS, Jennette JC: Clinical course of anti-neutrophil cytoplasmic autoantibodies-associated glomerulonephritis and systemic vasculitis. Ann Intern Med. 1990, 113: 656-663.PubMedView ArticleGoogle Scholar
- Sturrock AB, Franklion KF, Rao G, Marshall BC, Rebentisch MB, Lemons RS, Hoidal JR: Structure, chromosomal assignment, and expression of the gene for proteinase-3. J Biol Chem. 1992, 267: 21193-21199.PubMedGoogle Scholar
- Mayet WJ, Schwarting A, Orth T, Sibelius U, Hattar K, Meyer zum Büschenfelde KH: Signal transduction pathways of membrane expression of proteinase 3 (PR-3) in human endothelial cells. Eur J Clin Invest. 1997, 27: 165-170. 10.1046/j.1365-2362.1997.2160771.x.View ArticleGoogle Scholar
- Sibelius U, Hattar K, Schenkel A, Csernok E, Gross WL, Mayet WJ, Grimminger F: Influence of monoclonal antibodies against proteinase 3 on signal transduction and secondary cell reactions in human endothelial cells. Sarcoidosis. 1996, 13: 263-270.Google Scholar
- Burns A: Pulmonary vasculitis. Thorax. 1998, 53: 220-227.PubMedPubMed CentralView ArticleGoogle Scholar
- Müller-Ladner U, Kriegsmann J, Tschopp J, Gay R, Gay S: Demonstration of granzyme a and perforin messenger RNA in the synovium of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38: 477-484.PubMedView ArticleGoogle Scholar
- Hoffman GS, Kerr GS, Laevitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS: Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992, 116: 488-498.PubMedView ArticleGoogle Scholar
- Hoffman GS, Specks U: Antineutrophil cytoplasmatic antibodies. Arthritis Rheum. 1998, 41: 1521-1537.PubMedView ArticleGoogle Scholar
- Schwarting A, Schlaak JF, Wandel E, Meyer zum Büschenfelde KH, Mayet WJ: Human renal tubular epithelial cells as target cells for antibodies to proteinase 3 (c-ANCA). Nephrol Dial Transplant. 1997, 12: 916-923. 10.1093/ndt/12.5.916.PubMedView ArticleGoogle Scholar
- Srikanth S, Rado TA: PU.1 regulates the expression of the human neutrophil elastase gene. Biochem Biophys Acta. 1998, 1398: 215-223. 10.1016/S0167-4781(98)00039-6.PubMedGoogle Scholar
- Sturrock A, Franklin KF, Hoidal JR: Human proteinase-3 expression is regulated by PU.1 in conjunction with a cytidine-rich element. J Biol Chem. 1996, 271: 32392-32402. 10.1074/jbc.271.50.32392.PubMedView ArticleGoogle Scholar
- Ritter JH: Anti-neutrophil cytoplasmic autoantibodies and patterns of pulmonary disease. A spectrum of pathologic findings. Am J Clin Pathol. 1995, 104: 1-2.PubMedGoogle Scholar
- Just J, Moog-Lutz C, Houzel-Charavel A, Canteloup S, Grimfeld A, Witko-Sarsat N, Cayre YE: Proteinase 3 mRNA expression is induced in monocytes but not in neutrophils of patients with cystic fibrosis. FEBS Lett. 1999, 457: 437-440. 10.1016/S0014-5793(99)01098-4.PubMedView ArticleGoogle Scholar
- Mayet WJ, Csernok E, Szymkowiak C, Gross WL, Meyer zum Büschenfelde KH: Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis. Blood. 1993, 82: 1221-1229.PubMedGoogle Scholar
- Schwarting A, Hagen D, Odenthal M, Brockmann H, Dienes HP, Wandel E, Rumpelt HJ, Meyer zum Büschenfelde KH, Mayet WJ: Proteinase 3 mRNA expressed by human glomerular epithelial cells correlates with crescent formation in patients with Wegeners Granulomatosis. Kidney Int. 2000, 57: 2412-2422. 10.1046/j.1523-1755.2000.00100.x.PubMedView ArticleGoogle Scholar
- Mayet WJ, Helmreich-Becker I, Meyer zum Büschenfelde KH: The pathophysiology of anti-neutrophil cytoplasmic antibodies (ANCA) and their clinical relevance. Crit Rev Oncol Hematol. 1996, 23: 151-165. 10.1016/1040-8428(96)00202-8.PubMedView ArticleGoogle Scholar